Support for the efficiency of vaccine production with GMP-compliant liquid media.
In the vaccine manufacturing industry, there is a demand for streamlining the manufacturing process to ensure a stable supply of high-quality products. In particular, the quality of the culture media used for cell culture is a crucial factor that influences the efficacy and safety of vaccines. Mistakes in media preparation or variations in quality can lead to decreased manufacturing efficiency and quality issues with the products. Our liquid media is produced in a GMP-compliant manufacturing environment, providing stable quality to support the resolution of challenges in vaccine production. 【Usage Scenarios】 - Cell culture processes in vaccine manufacturing - Preparation processes for cell culture media - Stabilization of media quality 【Benefits of Implementation】 - Reduction of labor hours through outsourcing media preparation tasks - Decreased risk of preparation errors and equipment maintenance - Concentration of resources on core business (vaccine manufacturing)
Inquire About This Product
basic information
【Features】 - Manufacturing environment compliant with GMP - Production line capable of handling small to large quantities and various types - Extensive use of single-use equipment - Strict raw material management - Containers compatible with bottles and single-use bags 【Our Strengths】 We are a joint venture between Ajinomoto Co., Inc. and Koji Bio Co., Ltd. By combining Ajinomoto's high-quality amino acid-based media raw materials and formulation development technology with Koji Bio's advanced liquid media production technology, we provide high-quality liquid media.
Price information
Please contact us separately.
Delivery Time
※It will vary depending on the quantity, so please contact us separately.
Applications/Examples of results
For more details, please download the PDF or contact us.
catalog(3)
Download All CatalogsCompany information
In June 2018, we established Ajinomoto Koji Bio Co., Inc. as a joint venture between Ajinomoto Co., Inc. and Koji Bio Co., Inc. We combined Ajinomoto Co., Inc.'s high-quality amino acids as the foundation for culture media raw materials and their formulation development technology with Koji Bio Co., Inc.'s advanced liquid culture media production technology to launch a contract manufacturing company for clinical culture media necessary for regenerative medicine. Currently, we are engaged in contract manufacturing of liquid media and buffers for customers in cell therapy and biopharmaceuticals, enhancing our significance in the industry.




![[Customer Original Composition Medium Introduction Case] Regenerative Medicine Industry](https://image.mono.ipros.com/public/product/image/2087504/IPROS16690081183625342335.png?w=280&h=280)
![[Data] Caramelization phenomenon of liquid BI ampoules treated with autoclaving.](https://image.mono.ipros.com/public/product/image/e76/2001106783/IPROS24371793341470791090.png?w=280&h=280)


![★GMP Compliant [Buffer Contract Manufacturing Service]](https://image.mono.ipros.com/public/product/image/28b/2001528046/IPROS11360744701047854026.jpg?w=280&h=280)
![[Case Study on Culture Media] Establishing a Liquid Culture Media Supply System for a Major Biopharmaceutical Company](https://image.mono.ipros.com/public/default/object/noimage_l.gif?w=280&h=280)